OneDigital Investment Advisors buys shares in Viking Therapeutics, a biopharmaceutical firm with a $5.86B market cap.

OneDigital Investment Advisors LLC has acquired 3,260 shares in Viking Therapeutics, Inc., valued at around $206,000, joining other institutional investors in modifying their stakes in the company. Viking Therapeutics, a biopharmaceutical firm specializing in therapies for metabolic and endocrine disorders, has a market cap of $5.86 billion and is currently in Phase IIb trials for its lead drug, VK2809, targeting liver diseases. Despite insider sales, institutional investors own 76.03% of the company's stock, and analysts have a positive outlook, setting a consensus price target of $109.73.

November 24, 2024
3 Articles